Dosimetry evaluation and uncertainty analysis of Cobalt-60 HDR brachytherapy for cervical cancer in resource-limited settings.

ABSTRACT:

Background

High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative. This study aims to evaluate the dosimetric performance and planning uncertainties associated with Co-60 HDR brachytherapy.

Methods

A retrospective dosimetric analysis was conducted on 30 patients with FIGO stage IIB-IIIB cervical cancer, eligable for Brachytherapy, were treated using CT-guided intracavitary HDR brachytherapy with Co-60 sources. Treatment plans were assessed for high-risk clinical target

SUBMITTER: M El-Doushy A 

PROVIDER: S-EPMC12420530 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature